These new data on amlitelimab in adults and adolescents with atopic dermatitis were announced by Sanofi.
2 minutes ago
Lund discusses a recent study detailing the comparatively lower greenhouse gas emissions caused by preventive care versus diabetes management.
2 hours ago
15 hours ago
In these new phase 3b/4 data from LEVEL UP, findings on switching from dupilumab to upadacitinib in patients with atopic dermatitis are explored.
18 hours ago
MacDougall discusses the Family Heart Foundation’s recent study indicating that very few adults with ASCVD are receiving guideline-directed therapy.